Labcorp Q2 revenue slightly beats estimates, lifts 2026 outlook
LH•Drivers behind the quarter
The company said increases in adjusted operating income and margin were due to organic growth and operating efficiencies.
It cited expansion in oncology offerings and high-growth specialty areas as drivers of business momentum.
Labcorp also pointed to acquisitions and launches of new diagnostic tests, including nationwide rollout of ColoSense and new genetic health panels, as contributing to growth.
The company boosted its share buyback by $1.0 bln.
Analyst coverage and valuation
The current average analyst rating on the shares is "buy", with 16 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell" recommendations.
The average consensus recommendation for the healthcare facilities & services peer group is "buy".
Wall Street's median 12-month price target for Labcorp Holdings Inc is $320.00, about 4.2% above its July 29 closing price of $307.15.
The stock recently traded at 16 times the next 12-month earnings vs. a P/E of 15 three months ago.
